Holy Basil (Tulsi) 1,000mg Cuts Cortisol 22% and HbA1c 0.4% in Stressed Prediabetics — 12-Week RCT

A 12-week RCT in patients with both chronic stress and prediabetes found that 1,000mg of holy basil (Indian name: Tulsi) reduced salivary cortisol by 22%, HbA1c by 0.4%, and blood pressure by 8/6 mmHg simultaneously. Led by India’s BHU (Banaras Hindu University) Medical College and published in the January 2026 issue of Journal of Ethnopharmacology, the trial enrolled 124 patients and demonstrated superiority over placebo across all primary and secondary endpoints.

Researchers randomized 124 patients (mean age 44, 51% female) meeting both chronic stress (PSS >20) and prediabetes (HbA1c 5.7~6.4%) criteria to OciBest standardized holy basil 1,000mg (500mg morning + 500mg evening) or placebo. Primary endpoints were 12-week salivary diurnal cortisol AUC and HbA1c change. Secondary endpoints were fasting glucose, insulin resistance (HOMA-IR), blood pressure, GAD-7 anxiety, and hs-CRP.

Twelve-week results showed coordinated multi-axis recovery. Salivary diurnal cortisol mean fell from 8.2 to 6.4 nmol/L (-22%) versus -5% in placebo. HbA1c dropped from 6.1% to 5.7% (-0.4 percentage points) versus -0.1 in placebo, a four-fold gap. Fasting glucose fell 14 mg/dL and HOMA-IR by 0.8, both superior to placebo. Systolic/diastolic blood pressure dropped 8/6 mmHg (placebo -2/-1), clinically meaningful for stage 1 hypertension.

Cardiovascular risk marker hs-CRP fell from 3.2 to 2.1 mg/L (-34%) in the holy basil group versus -8% in placebo. Oxidative stress marker MDA dropped 28% and antioxidant enzyme SOD rose 18%. As cortisol declined, oxidative and inflammatory burden eased in parallel. The four axes of cortisol, insulin resistance, oxidative stress, and inflammation loosened together.

Psychological metrics also improved meaningfully. GAD-7 anxiety dropped from 12.4 to 8.9 (-28%) versus -9% in placebo. PSS-10 stress fell 24% and sleep quality (PSQI) recovered 32%. Notably, MBI emotional exhaustion also dropped 19%, consistent with the clinical observation that burnout and chronic stress overlap on the neuroendocrine-metabolic axis.

Holy basil (Ocimum tenuiflorum, syn. O. sanctum) has been called the “queen of herbs” in Indian Ayurveda for 3,000 years. Active molecules include ursolic acid, ocimumin, eugenol, and carnosic acid. The OciBest standardized extract is calibrated to ≥2.5% ursolic acid. Mechanisms include 11β-HSD1 inhibition (reducing cortisol synthesis), AMPK activation (improving insulin sensitivity), Nrf2 activation (antioxidant), and COX-2 inhibition (anti-inflammatory).

The detailed analysis showed the 12-week cumulative effect was key. At week 4, cortisol -8% and HbA1c -0.1% were modest. Effects accelerated by week 8 (cortisol -16%, HbA1c -0.2%) and peaked at week 12. This suggests holy basil acts as a gradual neuroendocrine-metabolic recalibrator rather than a short-term sedative. In a 24-week follow-up, effects were sustained, and progression to diabetes was three times less frequent than in placebo.

Adverse events were 6.5% in the holy basil group (mild GI discomfort, hypoglycemia) versus 4.9% in placebo, no significant difference. However, patients on anticoagulants (warfarin), pregnant women, and those with hyperthyroidism should consult a clinician. Patients on diabetes medications (metformin, SGLT2 inhibitors) face hypoglycemia risk and should monitor glucose. Korea’s MFDS recognizes holy basil as a food ingredient, allowing distribution as a general food.

In Korea, 24% of adults aged 30~50 are prediabetic and 39% report chronic stress per the 2026 KNHANES. For office workers in this overlap matrix, holy basil 1,000mg over 12 weeks is emerging as a first-line option before pharmaceutical prescription. Eligibility: PSS >20, HbA1c 5.7~6.4%, no anticoagulant use. Verifying ≥2.5% ursolic acid standardization (OciBest, KrishnaTulsi, etc.) on the label is the prerequisite for efficacy.